Report on Global Spirometers by DataM Intelligence estimates the market to grow at a CAGR of 11.2 % during the forecast period 2023 - 2030. Spirometers usage in functioning of the lungs is on the rise. Demand from hospitals and Clinical Laboratories in North America is booming. Competitive rivalry intensifies with Hill-Rom Inc, Teleflex Incorporated, Vitalograph and others operating in the market.
A spirometer is a medical device used to measure the proper functioning of the lungs, where the volume of air inhaled and exhaled from the lungs is measured after maximum inhalation by the patient. Spirometer helps identify different respiratory diseases, such as bronchitis, chronic lung diseases that are obstructive, emphysema, asthma, and other breathing diseases, for screening in an occupational environment. A spirometer is used to analyze lung function before surgery and predict respiratory diseases.
Metrics |
Details |
Market CAGR |
11.2% |
Segments Covered |
By Type, By Technology, By Application, By End-User and By Region |
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
Fastest Growing Region |
Asia Pacific |
Largest Market Share |
North America |
The spirometers market growth is driven by the rising cases of COPD across the world, growing preference for home healthcare, and technological advancements are expected to drive the market.
Growing technological advancements, is expected to drive the growth in the forecast period
Around 2.0 billion people worldwide are exposed to air pollution regularly, both indoor and outdoor. Pollutants and irritants have various adverse effects on the lungs. To simplify the complex procedure involved in pulmonary function testing for patients and medical professionals, companies are developing spirometers with improved design and features. The main objective is to develop spirometers with higher yield and improved patient comfort without complications. In addition, companies are also adopting innovative technological improvements to make the testing procedures easier and simpler for patients.
Preference for home healthcare has been increased over the past few years. The idea of providing treatment to patients in the comfort of their homes is a major factor propelling the growth of the market for a spirometer. The development of tele-spirometers is a result of the rising preference for home healthcare. For instance, NuvoAir-a Swedish respiratory health startup-developed a technology platform that enables users to conduct at-home lung function assessments.
Dearth of skilled professionals is likely to hamper the market growth
Despite the higher prevalence of asthma and COPD globally, certain factors limit the adoption of these devices. The lack of a skilled workforce for conducting diagnostic tests is anticipated to restrain the growth. Pulmonary function testing is a series of different breathing tests that trained pulmonary function technologists can lead. However, there is a shortage of skilled healthcare professionals in developing regions. The emigration of healthcare workers to developed countries is the main reason for this shortage. The tendency to migrate to higher economic countries is primarily owing to the search for better wages and working conditions. For instance, according to the World Health Organization (WHO), it is estimated that there is about 14.5 million global health workforce shortage faced by the Sustainable Development Goals (SDGs) and the Universal Health Coverage (UHC). Out of this, the African region faces the highest health workforce shortage that is expected to reach 6.1 million by 2030, and limited awareness in underdeveloped countries is anticipated to hamper the market growth.
COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020. This pandemic has disrupted growth in many economies across various domains. Respiratory diseases are among the leading causes of death globally, making up five of the top 30 causes. Chronic obstructive pulmonary disease (COPD) is the third-most-leading cause of death. COVID-19 outbreak has caused an increased incidence of respiratory diseases. The pandemic has caused disruption in health systems all over the world. It is anticipated that there will be a surge in the number of ARDS patients requiring respiratory support, and there may be an increase in the demand for spirometers.
The portable spirometers segment is expected to hold largest share in this market segment
Portable spirometers that are lightweight and compact have become popular as these devices can store hundreds of diagnostic test results and print the results on standard printers. Moreover, results can be transferred to flash drives and patients’ Electronic Medical Records (EMRs). For instance, on March 16, 2021, Vyaire Medical announced the launch of the AioCare (HealthUp SA, Poland) mobile spirometry system in more than 15 countries across Europe, the Middle East, and Australia. AioCare consists of a portable spirometer connected to a dedicated smartphone app and an online panel that allows physicians and patients to share and discuss results through remote tracking and secure communication. It also performs high-quality patient monitoring via advanced digital connectivity at home.
The COPD segment is expected to hold largest share in this market segment
The COPD segment dominated the market for a spirometer and accounted for the largest revenue share. This is due to the high number of people suffering worldwide from mild to severe COPD. According to the American Lung Association, the global burden of disease study reported a prevalence of 16.4 million people, or 6.6% of adults of COPD, globally, in 2018. According to the World Health Organization (WHO), it is also estimated that 3.23 million deaths deaths were caused by the disease in 2019, (that is, 5% of all deaths, globally, in that year). However, more than 90% of COPD deaths occur in low and middle-income countries.
North America region holds the largest market share of global spirometers market
North America has dominated the spirometers market, and the dominance of the market is mainly attributable to the increasing prevalence of respiratory diseases. Due to the increasing prevalence of COPD and asthma, there is the increased usage of the spirometer, which helps control the disease, and is widely used by physicians in the hospitals. According to the CDC, the costs involved in treating COPD are likely to reach USD 90 billion by 2020 from USD 59 billion in 2016. The United States is also found to be an early adopter of the technologies, which helps in reducing COPD rates. New technological improvements such as the adoption of artificial intelligence will create growth opportunities for new players to enter the US market. For instance, In April 2021, Vitalograph launched next-generation Pneumotrac spirometer in the United States, along with its upgraded Spirotrac 6 software. Hence, with the factors mentioned above, the market is expected to drive in the forecast period.
The global spirometers market is highly competitive with presence of global companies. Some of the key players which are contributing to the growth of the market include VYAIRE MEDICAL, INC, MGC Diagnostics Corporation, NDD Medical Technologies, Hill-Rom, Inc, Smiths Medical, Teleflex Incorporated, FUKUDA SANGYO CO., LTD, Jones Medical Instrument Company, Vitalograph, Midmark Corporation and KoKo, LLC. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the software as a medical device globally. For instance, in January 2020, NuvoAir partnered with Roche Italy, wherein Roche will distribute NuvoAir’s digital respiratory technology to cystic fibrosis centers across Italy. This is expected to intensify the competition in the market over the forecast period.
Key Companies to Watch
MGC Diagnostics Corporation
Overview: MGC Diagnostics is a global medical technology company dedicated to cardiorespiratory health solutions. Headquartered in Saint Paul, Minnesota, USA, MGC Diagnostics Corporation develops, manufactures and markets non-invasive diagnostic systems for detecting, classifying and managing the cardiorespiratory disease.
Product Portfolio: The key product categories are pulmonary function test, metabolic test (cpet/cpx), indirect calorimetry, software.
Key Developments: In 2020, the all-new Ascent cardiorespiratory diagnostic software was designed from the ground up to be the most advanced testing software platform available. This versatile software combines pulmonary function testing, data review and reporting into one powerful application.